Q-omics provides the consensus-scored SPACA7 profile across patient tissues and cancer cell-line models. SPACA7 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, SPACA7 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, SPACA7 RNA expression shows 6,280 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, COAD, and STAD as cancer lineages where SPACA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPACA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPACA7 survival associations across molecular data types. SPACA7 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPACA7 RNA expression–survival associations across cancer types. High SPACA7 expression shows unfavorable associations in READ, BRCA, CHOL, LGG and THCA, but favorable associations in CESC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for SPACA7 RNA expression.
This table summarizes SPACA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SPACA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPACA7 shows lower tumor expression in CHOL and LIHC and higher tumor expression in COAD and THCA. The COAD box plot shows higher SPACA7 RNA expression in tumor versus normal tissue (log2 FC = +0.022, t-test p = .017).
This table shows molecular features associated with SPACA7 in patient tissues and cancer cell lines. In patient samples, SPACA7 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SPACA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
